1. Home
  2. GBDC vs HAE Comparison

GBDC vs HAE Comparison

Compare GBDC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Golub Capital BDC Inc.

GBDC

Golub Capital BDC Inc.

HOLD

Current Price

$12.72

Market Cap

3.5B

Sector

Finance

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$57.57

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBDC
HAE
Founded
2007
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
2010
1991

Fundamental Metrics

Financial Performance
Metric
GBDC
HAE
Price
$12.72
$57.57
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$14.17
$86.00
AVG Volume (30 Days)
2.5M
1.1M
Earning Date
02-04-2026
02-05-2026
Dividend Yield
12.12%
N/A
EPS Growth
N/A
43.84
EPS
1.24
3.65
Revenue
$857,084,000.00
$1,318,275,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.86
P/E Ratio
$10.35
$16.28
Revenue Growth
9.80
N/A
52 Week Low
$12.28
$47.32
52 Week High
$16.01
$87.32

Technical Indicators

Market Signals
Indicator
GBDC
HAE
Relative Strength Index (RSI) 38.35 21.66
Support Level $12.36 $56.99
Resistance Level $12.98 $60.50
Average True Range (ATR) 0.28 2.38
MACD -0.07 -0.81
Stochastic Oscillator 28.81 4.25

Price Performance

Historical Comparison
GBDC
HAE

About GBDC Golub Capital BDC Inc.

Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: